An expert panel convened by the American Society of Bone and Mineral Research has recommended new warnings on Fosamax for bone fractures. Fosamax is prescribed for treatment of osteoporosis and is used by more than 20 million people having generated over $3 billion in annual sales for Merck. A number of lawsuits have been filed for thigh bone fractures against Merck for failing to adequately research their medications or warn users about the risks of bone breaks. In addition it appears to cause injuries to the jaw in a condition known as osteonecrosis of the jaw which causes portions of the jaw to decay or die. For more information contact Jeffrey Newman.